» Articles » PMID: 10950786

Evaluation of Human Antimycobacterial Immunity Using Recombinant Reporter Mycobacteria

Overview
Journal J Infect Dis
Date 2000 Aug 19
PMID 10950786
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

A novel in vitro whole blood model was developed to study human antimycobacterial immunity. Recombinant reporter mycobacteria were used to enumerate the bacteria, and interactions between host immune cells and mycobacteria were studied using whole blood rather than cell fractions. The ability of healthy tuberculin-positive and tuberculin-negative individuals to restrict mycobacterial growth was compared. Growth of luminescent mycobacteria was significantly lower in blood samples of tuberculin-positive individuals than in blood samples of tuberculin-negative individuals (P=.005). Restricted mycobacterial growth was associated with significantly higher production of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma (P=.01 and.004, respectively). Inhibition of the TNF-alpha and IFN-gamma response pathways by neutralizing monoclonal antibodies increased mycobacterial growth in whole blood. This model is the first functional assay in which individual variations in cell-mediated immunity are shown to correlate with differences in ability to control mycobacterial growth. It provides a new tool for studying human mycobactericidal mechanisms and, potentially, for the evaluation of improved vaccines.

Citing Articles

Development and application of the direct mycobacterial growth inhibition assay: a systematic review.

Painter H, Harriss E, Fletcher H, McShane H, Tanner R Front Immunol. 2024; 15:1355983.

PMID: 38380319 PMC: 10877019. DOI: 10.3389/fimmu.2024.1355983.


Whole Blood Mycobacterial Growth Assays for Assessing Human Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis.

Bok J, Hofland R, Evans C Front Immunol. 2021; 12:641082.

PMID: 34046032 PMC: 8144701. DOI: 10.3389/fimmu.2021.641082.


The direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells.

Tanner R, Hoogkamer E, Bitencourt J, White A, Boot C, Sombroek C F1000Res. 2021; 10:257.

PMID: 33976866 PMC: 8097740. DOI: 10.12688/f1000research.51640.2.


A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.

Tanner R, White A, Boot C, Sombroek C, OShea M, Wright D NPJ Vaccines. 2021; 6(1):3.

PMID: 33397986 PMC: 7782578. DOI: 10.1038/s41541-020-00263-7.


Protection against mycobacterial infection: A case-control study of mycobacterial immune responses in pairs of Gambian children with discordant infection status despite matched TB exposure.

Roy R, Sambou B, Sissoko M, Holder B, Gomez M, Egere U EBioMedicine. 2020; 59:102891.

PMID: 32675024 PMC: 7502674. DOI: 10.1016/j.ebiom.2020.102891.